Skip to main content

Table 1 Clinical features of metastatic colorectal cancer patients treated with irinotecan-based therapy

From: DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer

Characteristics Patients (N = 67)
Median age-years (range) 62 (33–79)
Sex
 Male 47 (70%)
 Female 20 (30%)
Median CEA (range, ng/mL) 16 (0–2066)
Performance status WHO
 0 29 (43%)
 1 35 (52%)
 2 3 (5%)
Site of primary tumor
 Colon 35 (52%)
 Rectum 32 (48%)
METASTASIS
 Liver 31 (47%)
 Liver & other 19 (28%)
 Other 15 (22%)
 N.A. 2 (3%)
KRAS
 Wild-type 35 (52%)
 Mutated 26 (39%)
 N.A. 6 (9%)
BRAF
 Wild-type 60 (90%)
 Mutated 7 (10%)
Biologic treatment
 Bevacizumab 23 (34%)
 Cetuximab 7 (11%)
 None 37 (55%)
TOPO I expression level
 High 21 (31%)
 Low 20 (30%)
 N.A. 26 (39%)
DEK expression level
 High 21 (31%)
 Low 46 (69%)
  1. N.A.: not available. Other refers to lung, lymph node and/or peritoneal metastasis.